Arcus Biosciences, Inc.
RCUS
$9.16
$0.030.33%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -80.69% | -16.13% | 50.00% | 34.48% | 480.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -80.69% | -16.13% | 50.00% | 34.48% | 480.00% |
| Cost of Revenue | 11.93% | 8.60% | 50.00% | 11.11% | 34.57% |
| Gross Profit | -361.11% | -20.97% | -50.00% | 45.00% | 164.29% |
| SG&A Expenses | -12.50% | -3.45% | 0.00% | 7.14% | 6.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.38% | 5.74% | 36.61% | 29.46% | 27.03% |
| Operating Income | -3,150.00% | -13.19% | -31.25% | -27.71% | 104.65% |
| Income Before Tax | -2,700.00% | -16.25% | -33.33% | -25.68% | 94.87% |
| Income Tax Expenses | -- | 0.00% | -- | -- | -- |
| Earnings from Continuing Operations | -2,700.00% | -16.05% | -29.58% | -24.00% | 95.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,700.00% | -16.05% | -29.58% | -24.00% | 95.00% |
| EBIT | -3,150.00% | -13.19% | -31.25% | -27.71% | 104.65% |
| EBITDA | -1,800.00% | -13.64% | -30.38% | -28.40% | 108.33% |
| EPS Basic | -2,353.02% | 5.08% | -5.77% | 0.36% | 95.77% |
| Normalized Basic EPS | -713.28% | 4.92% | -8.82% | -0.98% | 117.37% |
| EPS Diluted | -2,353.02% | 5.08% | -5.77% | 0.36% | 95.77% |
| Normalized Diluted EPS | -713.28% | 4.92% | -8.82% | -0.98% | 117.37% |
| Average Basic Shares Outstanding | 14.15% | 22.27% | 22.52% | 24.45% | 18.08% |
| Average Diluted Shares Outstanding | 14.15% | 22.27% | 22.52% | 24.45% | 18.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |